Clearside Biomedical (CLSD) Tops Q2 EPS by 3c

Clearside Biomedical (NASDAQ: CLSD) reported Q2 EPS of ($0.10), $0.03 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $90 thousand versus the consensus estimate of $151.8 thousand.

For earnings history and earnings-related data on Clearside Biomedical (CLSD) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Increasing unusual option volume: BLZE VRNS PRIM EWC OPTU SW DOMO NICE MIR
• SK hynix files for Nasdaq IPO under ticker symbol SKHY